• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[浅表性膀胱肿瘤中的核仁组织区。37例观察的预后分析]

[Nucleolar organizers in superficial bladder tumors. Prognostic analysis of 37 observations].

作者信息

Clement T, Visseaux-Coletto B, Adnet J J, Ploton D, Lardennois B

机构信息

Service d'Urologie, CHU Robert Debré, Reims.

出版信息

Prog Urol. 1991 Apr;1(2):216-29.

PMID:1844824
Abstract

Nucleolar Organisers (NORs) are intranucleolar segments of DNA coding for ribosomal RNA. The agyrophilic proteins (AgNOR) associated with NORs allow them to be cytolabelled on paraffin sections. The number of NORs (NOR index) is correlated with cellular proliferation and has a diagnostic and prognostic value in neoplastic disease. The AgNOR method was analysed in a series of 37 superficial bladder tumours with different clinical courses. The NORs were counted in normal urothelium, on superficial tumours used to establish the diagnosis of the disease and on recurrent superficial tumours. The NOR index was 4.54 for normal urothelium, 5.89 for non-invasive superficial tumours, 7.33 for invasive superficial tumours, and 9.75 for invasive recurrences. These results demonstrate an increase in nucleolar argyrophilia with invasion and invasive potential of superficial bladder tumours which were initially homogeneous for stage and grade. The AfNOR method could constitute a new method of early histoprognostic evaluation for urothelial tumours.

摘要

核仁组织者区(NORs)是编码核糖体RNA的DNA的核仁内片段。与NORs相关的嗜银蛋白(AgNOR)使它们能够在石蜡切片上进行细胞标记。NORs的数量(NOR指数)与细胞增殖相关,在肿瘤性疾病中具有诊断和预后价值。对一系列37例具有不同临床病程的浅表性膀胱肿瘤进行了AgNOR方法分析。在正常尿路上皮、用于确诊疾病的浅表肿瘤以及复发性浅表肿瘤中对NORs进行计数。正常尿路上皮的NOR指数为4.54,非侵袭性浅表肿瘤为5.89,侵袭性浅表肿瘤为7.33,侵袭性复发肿瘤为9.75。这些结果表明,对于最初在分期和分级上较为一致的浅表性膀胱肿瘤,随着侵袭和侵袭潜能的增加,核仁嗜银性增强。AgNOR方法可构成一种用于尿路上皮肿瘤早期组织学预后评估的新方法。

相似文献

1
[Nucleolar organizers in superficial bladder tumors. Prognostic analysis of 37 observations].[浅表性膀胱肿瘤中的核仁组织区。37例观察的预后分析]
Prog Urol. 1991 Apr;1(2):216-29.
2
Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor.增殖细胞核仁组成区嗜银蛋白对浅表性膀胱肿瘤局部复发具有预测价值。
J Urol. 1999 Jul;162(1):63-8. doi: 10.1097/00005392-199907000-00016.
3
[Nucleolar organizer region in bladder cancer. Relationship with histologic grade, stage, and prognosis].[膀胱癌中的核仁组织区。与组织学分级、分期及预后的关系]
Actas Urol Esp. 1994 Mar;18(3):204-6.
4
The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.复发性高危浅表性膀胱肿瘤患者根治性膀胱切除术的最佳时机。
BJU Int. 2004 Dec;94(9):1258-62. doi: 10.1111/j.1464-410X.2004.05228.x.
5
[Argentophilic nucleolar organizers and prognosis for patients with surface and locally advanced transitional cell cancer of the urinary bladder].[嗜银性核仁组织者与膀胱表浅及局部进展性移行细胞癌患者的预后]
Urologiia. 2005 Jan-Feb(1):5-9.
6
Nucleolar organiser regions (NORs) in bladder cancer; relation to histological grade, clinical stage and prognosis.
Anticancer Res. 1991 Jan-Feb;11(1):75-80.
7
DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder.膀胱浅表性移行细胞癌中的DNA含量及增殖活性
Anticancer Res. 1997 Jan-Feb;17(1B):781-6.
8
Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.前列腺干细胞抗原可预测膀胱浅表性移行细胞癌的肿瘤复发。
BJU Int. 2006 Jun;97(6):1202-7. doi: 10.1111/j.1464-410X.2006.06153.x.
9
Role of proliferative activity estimated by bromodeoxyuridine labeling index in determining predictive factors of recurrence in superficial intermediately malignant bladder tumors.通过溴脱氧尿苷标记指数评估的增殖活性在确定浅表性中度恶性膀胱肿瘤复发预测因素中的作用。
J Urol. 1996 Jul;156(1):63-9.
10
An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.105例膀胱癌组织中组织蛋白酶D表达的免疫组化及预后评估
J Urol. 1995 Jul;154(1):237-41.